Literature DB >> 7116148

Classical conditioning of front paw and hind paw footshock induced analgesia (FSIA): naloxone reversibility and descending pathways.

L R Watkins, D A Cobelli, D J Mayer.   

Abstract

Opiate and non-opiate footshock induced analgesia (FSIA) has recently been observed to be differentially elicited dependent upon the body region shocked; front paw and hind paw shock produce opiate and non-opiate analgesia, respectively. Previous studies have shown that footshock can also produce classically conditioned analgesia; that is, when shock is delivered to an animal, environmental cues become associated with the noxious stimulus such that these cues become capable, in and of themselves, of producing potent analgesia. The present series of experiments examined analgesia classically conditioned to either front paw or hind paw shock. The non-electrified shock grid served as the conditioned stimulus (CS), 90-s footshock as the unconditioned stimulus (UCS) and tail-flick inhibition as the unconditioned response (UCR). Following CS-UCS pairings, exposure to the non-electrified grid reliably produced prolonged analgesia. This classically conditioned analgesia appears to involve endogenous opioids, regardless of the body region shocked during conditioning trials, since the analgesia is attenuated by systemic naloxone and shows cross-tolerance to morphine. A spinal opioid site is involved since 1 microgram of naloxone delivered directly to the lumbosacral cord antagonizes the analgesia. Like front paw (opiate) FSIA, CCA can be prevented but cannot be reversed by naloxone; naloxone can antagonize classically conditioned analgesia only if it is delivered prior to exposure to the conditioned stimulus. Lastly, a similarity was recognized between classically conditioned analgesia and the analgesia induced by morphine, brain stimulation, front paw shock and hind paw shock in that all are mediated via descending pathways within the dorsolateral funiculus of the spinal cord.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7116148     DOI: 10.1016/0006-8993(82)91125-8

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  8 in total

1.  Neural organization of the defensive behavior system responsible for fear.

Authors:  M S Fanselow
Journal:  Psychon Bull Rev       Date:  1994-12

2.  Classical conditioning of analgesic and hyperalgesic pain responses without conscious awareness.

Authors:  Karin Jensen; Irving Kirsch; Sara Odmalm; Ted J Kaptchuk; Martin Ingvar
Journal:  Proc Natl Acad Sci U S A       Date:  2015-05-15       Impact factor: 11.205

Review 3.  Mechanisms of placebo analgesia: A dual-process model informed by insights from cross-species comparisons.

Authors:  Scott M Schafer; Stephan Geuter; Tor D Wager
Journal:  Prog Neurobiol       Date:  2017-11-03       Impact factor: 11.685

4.  Imaging attentional modulation of pain in the periaqueductal gray in humans.

Authors:  Irene Tracey; Alexander Ploghaus; Joseph S Gati; Stuart Clare; Steve Smith; Ravi S Menon; Paul M Matthews
Journal:  J Neurosci       Date:  2002-04-01       Impact factor: 6.167

5.  Acute inflammation induces segmental, bilateral, supraspinally mediated opioid release in the rat spinal cord, as measured by mu-opioid receptor internalization.

Authors:  W Chen; J C G Marvizón
Journal:  Neuroscience       Date:  2009-03-17       Impact factor: 3.590

Review 6.  Classical conditioning and pain: conditioned analgesia and hyperalgesia.

Authors:  Gonzalo Miguez; Mario A Laborda; Ralph R Miller
Journal:  Acta Psychol (Amst)       Date:  2013-11-22

Review 7.  Learning from the spinal cord: how the study of spinal cord plasticity informs our view of learning.

Authors:  James W Grau
Journal:  Neurobiol Learn Mem       Date:  2013-08-20       Impact factor: 2.877

8.  Stress-induced antinociception in fish reversed by naloxone.

Authors:  Carla Patrícia Bejo Wolkers; Augusto Barbosa Junior; Leda Menescal-de-Oliveira; Anette Hoffmann
Journal:  PLoS One       Date:  2013-07-30       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.